Last update 08 May 2025

67Cu-SARTATE

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms-
Target
SSTR2
Action
antagonists
Mechanism
SSTR2 antagonists(Somatostatin receptor 2 antagonists)
Therapeutic Areas
NeoplasmsNervous System DiseasesOther Diseases+ [1]
Active Indication
High Risk NeuroblastomaNeuroblastoma recurrentRefractory Neuroblastoma+ [2]
Inactive Indication-
Originator Organization
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
Active Organization
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

3
Clinical Trials associated with 67Cu-SARTATE
NCT04023331
/ RecruitingPhase 1/2
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
NCT03936426
/ CompletedPhase 1/2
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial
ACTRN12618000309280
/ SuspendedPhase 1/2
Peptide Receptor Radionuclide Therapy administered to Participants withMeningioma with 67Cu-SARTATE™: A single-centre, open-label, nonrandomised,Phase I-IIa Theranostic Clinical Trial
100 Clinical Results associated with 67Cu-SARTATE
Login to view more data
100 Translational Medicine associated with 67Cu-SARTATE
Login to view more data
100 Patents (Medical) associated with 67Cu-SARTATE
Login to view more data
100 Deals associated with 67Cu-SARTATE
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk NeuroblastomaPhase 2
United States
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
18 Aug 2020
Neuroblastoma recurrentPhase 2
United States
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
18 Aug 2020
Refractory NeuroblastomaPhase 2
United States
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
18 Aug 2020
MeningiomaPhase 2
Australia
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
09 Jul 2018
Small Cell Lung CancerPreclinical
Australia
Clarity Pharmaceuticals Ltd.Clarity Pharmaceuticals Ltd.
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free